Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Convertible Debt (2016 - 2017)

Historic Convertible Debt for STRATA Skin Sciences (SSKN) over the last 4 years, with Q2 2017 value amounting to $13.4 million.

  • STRATA Skin Sciences' Convertible Debt rose 2366.96% to $13.4 million in Q2 2017 from the same period last year, while for Jun 2017 it was $13.4 million, marking a year-over-year increase of 2366.96%. This contributed to the annual value of $12.0 million for FY2016, which is N/A changed from last year.
  • STRATA Skin Sciences' Convertible Debt amounted to $13.4 million in Q2 2017, which was up 2366.96% from $12.7 million recorded in Q1 2017.
  • STRATA Skin Sciences' Convertible Debt's 5-year high stood at $13.4 million during Q2 2017, with a 5-year trough of $5.0 million in Q4 2014.
  • Its 4-year average for Convertible Debt is $10.2 million, with a median of $11.1 million in 2015.
  • As far as peak fluctuations go, STRATA Skin Sciences' Convertible Debt soared by 12599.37% in 2015, and later increased by 21.98% in 2016.
  • STRATA Skin Sciences' Convertible Debt (Quarter) stood at $5.0 million in 2014, then surged by 127.41% to $11.4 million in 2015, then increased by 5.76% to $12.0 million in 2016, then rose by 11.29% to $13.4 million in 2017.
  • Its Convertible Debt stands at $13.4 million for Q2 2017, versus $12.7 million for Q1 2017 and $12.0 million for Q4 2016.